![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » EISAI ANNOUNCES ESTABLISHMENT OF A PHARMACEUTICALS MARKETING SUBSIDIARY IN SWEDEN
EISAI ANNOUNCES ESTABLISHMENT OF A PHARMACEUTICALS MARKETING SUBSIDIARY IN SWEDEN
July 15, 2005
Eisai Co., Ltd. (Headquarters: Tokyo, President & CEO: Haruo Naito) announced on July 8, 2005, the establishment of a pharmaceuticals marketing subsidiary, Eisai AB, in Sweden to expand business in the four Nordic countries (Sweden, Denmark, Finland and Norway). Eisai AB is owned by Eisai Europe Limited (Headquarters: London, President: Yutaka Tsuchiya). In the Nordic market, Eisai AB plans to sell and promote pharmaceuticals mainly in the neurology area including the anti-epileptic drugs Zonegran and Inovelon, for which a marketing application has been submitted to the European Medicines Evaluation Agency. The newly established subsidiary company will also promote active business development, and aims at establishing an efficient and profitable business framework.
PharmaLive (http://www.pharmalive.com/News/index.cfm?articleid=256193&categoryid=54)
KEYWORDS Daily International Pharma Alert
Upcoming Events
-
21Oct